|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.80 EUR | +0.85% |
|
+3.48% | -7.03% |
| 02-11 | Formycon, Lotus Sign License Deal for Keytruda Biosimilar in Asia-Pacific Region | MT |
| 02-11 | Swiss stocks - Factors to watch on February 11 | RE |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | -5.56 | -11.72 | -2.4 | -0.06 | -1.76 | |||||
Return on Total Capital | -6.17 | -13.4 | -4.74 | -0.11 | -2.92 | |||||
Return On Equity % | -10.2 | -21.72 | 17.45 | 17.64 | -26.06 | |||||
Return on Common Equity | -10.2 | -21.72 | 17.45 | 17.64 | -26.06 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 25.6 | 2.72 | 28.41 | 30 | 21.29 | |||||
SG&A Margin | 29.31 | 35.16 | 30.33 | 18.18 | 30.7 | |||||
EBITDA Margin % | -14.1 | -33.45 | -40.05 | -0.28 | 163.82 | |||||
EBITA Margin % | -16.12 | -35.3 | -41.62 | -1 | -22.75 | |||||
EBIT Margin % | -16.77 | -36 | -41.72 | -1.05 | -33.68 | |||||
Income From Continuing Operations Margin % | -17.31 | -36.46 | 84.69 | 97.55 | -180.37 | |||||
Net Income Margin % | -17.31 | -36.46 | 84.69 | 97.55 | -180.37 | |||||
Net Avail. For Common Margin % | -17.31 | -36.46 | 84.69 | 97.55 | -180.37 | |||||
Normalized Net Income Margin | -10.65 | -22.83 | 53.82 | -14.12 | -32.37 | |||||
Levered Free Cash Flow Margin | -9.92 | -28.19 | -56.19 | -24.44 | 96.36 | |||||
Unlevered Free Cash Flow Margin | -9.73 | -27.91 | -56 | -24.38 | 97.33 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.53 | 0.52 | 0.09 | 0.09 | 0.08 | |||||
Fixed Assets Turnover | 9.51 | 10.9 | 4.26 | 6.52 | 5.18 | |||||
Receivables Turnover (Average Receivables) | 5.79 | 5.05 | 3.1 | 3.56 | 2.37 | |||||
Inventory Turnover (Average Inventory) | 31.02 | 23.27 | 78.01 | 104.8 | 150.45 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 7.05 | 3.84 | 0.6 | 0.97 | 2.8 | |||||
Quick Ratio | 6.86 | 3.33 | 0.5 | 0.8 | 2.14 | |||||
Operating Cash Flow to Current Liabilities | -0.71 | -1.43 | -0.37 | -0.14 | -0.69 | |||||
Days Sales Outstanding (Average Receivables) | 63.17 | 72.28 | 117.72 | 102.52 | 154.65 | |||||
Days Outstanding Inventory (Average Inventory) | 11.8 | 15.69 | 4.68 | 3.48 | 2.43 | |||||
Average Days Payable Outstanding | 46.6 | 45.99 | 112.18 | 92.91 | 113.07 | |||||
Cash Conversion Cycle (Average Days) | 28.37 | 41.98 | 10.22 | 13.1 | 44.02 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | - | - | 13.83 | 5.87 | 2.29 | |||||
Total Debt / Total Capital | - | - | 12.15 | 5.55 | 2.24 | |||||
LT Debt/Equity | - | - | 7.74 | 1.56 | 1.97 | |||||
Long-Term Debt / Total Capital | - | - | 6.8 | 1.48 | 1.93 | |||||
Total Liabilities / Total Assets | 10 | 15.47 | 58.23 | 43.53 | 40.15 | |||||
EBIT / Interest Expense | -54.38 | -80.16 | -141.82 | -10.2 | -21.55 | |||||
EBITDA / Interest Expense | -45.71 | -74.48 | -127.91 | 11.35 | 105.97 | |||||
(EBITDA - Capex) / Interest Expense | -50.99 | -78.72 | -132.32 | -1.51 | 104.55 | |||||
Total Debt / EBITDA | - | - | -3.08 | 32.53 | 0.09 | |||||
Net Debt / EBITDA | 8.75 | 2.04 | -2.47 | 2.75 | -0.27 | |||||
Total Debt / (EBITDA - Capex) | - | - | -2.98 | -244.1 | 0.09 | |||||
Net Debt / (EBITDA - Capex) | 7.85 | 1.93 | -2.39 | -20.67 | -0.27 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 3.23 | 8 | 16.07 | 82.83 | -10.32 | |||||
Gross Profit, 1 Yr. Growth % | -20.13 | -88.52 | 19.41 | 93.05 | -36.35 | |||||
EBITDA, 1 Yr. Growth % | 254.46 | 156.12 | 27.67 | -98.69 | -53.44K | |||||
EBITA, 1 Yr. Growth % | 142.67 | 127.24 | 26.52 | -95.42 | 1.94K | |||||
EBIT, 1 Yr. Growth % | 152.52 | 131.73 | 26.63 | -95.2 | 2.78K | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 158.39 | 127.4 | -370.82 | 110.59 | -265.81 | |||||
Net Income, 1 Yr. Growth % | 158.39 | 127.4 | -370.82 | 110.59 | -265.81 | |||||
Normalized Net Income, 1 Yr. Growth % | 153.51 | 131.49 | -357.59 | -129.21 | 105.66 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 134.9 | 126.07 | -315.2 | 82.24 | -252.22 | |||||
Accounts Receivable, 1 Yr. Growth % | 40.13 | 12.37 | 29.63 | 82.05 | 9 | |||||
Inventory, 1 Yr. Growth % | 203.77 | 50.08 | 173.21 | -18.21 | -43.9 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | -5.41 | -6.23 | 36.59 | 7.04 | 18.2 | |||||
Total Assets, 1 Yr. Growth % | 41.16 | -12.26 | 1.11K | 4.29 | -13.33 | |||||
Tangible Book Value, 1 Yr. Growth % | 41.94 | -18.02 | -419.76 | -71.55 | -135.32 | |||||
Common Equity, 1 Yr. Growth % | 41.12 | -17.59 | 537.99 | 40.99 | -8.14 | |||||
Cash From Operations, 1 Yr. Growth % | 244.63 | 177.78 | 41.37 | -47.83 | 135.79 | |||||
Capital Expenditures, 1 Yr. Growth % | -39.54 | 26.16 | 39.85 | 86.75 | 50.15 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 9.34K | 194.94 | 163.05 | -18.95 | -453.52 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 18.07K | 197.58 | 162.9 | -18.89 | -458.04 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | -10.78 | 5.59 | 11.32 | 45.67 | 28.04 | |||||
Gross Profit, 2 Yr. CAGR % | -31.6 | -69.72 | 23.37 | 51.83 | 10.85 | |||||
EBITDA, 2 Yr. CAGR % | -22.44 | 201.32 | 69.84 | -87.33 | 164.58 | |||||
EBITA, 2 Yr. CAGR % | -11.97 | 139.56 | 64.55 | -76.41 | -3.35 | |||||
EBIT, 2 Yr. CAGR % | -10.2 | 141.92 | 64.63 | -75.86 | 17.45 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | -8.63 | 142.41 | 131.27 | 138.81 | 86.86 | |||||
Net Income, 2 Yr. CAGR % | -8.63 | 142.41 | 131.27 | 138.81 | 86.86 | |||||
Normalized Net Income, 2 Yr. CAGR % | -9.35 | 142.25 | 134.69 | 11.14 | -22.5 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | -15.44 | 130.45 | 98.06 | 98.04 | 66.55 | |||||
Accounts Receivable, 2 Yr. CAGR % | 15.5 | 25.48 | 41.64 | 53.62 | 40.87 | |||||
Inventory, 2 Yr. CAGR % | 0.81 | 113.57 | 151.88 | 49.48 | -32.26 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 0.4 | -5.81 | 11.58 | 20.92 | 12.48 | |||||
Total Assets, 2 Yr. CAGR % | 38.13 | 11.29 | 225.5 | 254.84 | -4.92 | |||||
Tangible Book Value, 2 Yr. CAGR % | 44.21 | 7.87 | 62.71 | -4.62 | -68.3 | |||||
Common Equity, 2 Yr. CAGR % | 43.07 | 7.84 | 130.88 | 199.92 | 13.81 | |||||
Cash From Operations, 2 Yr. CAGR % | -38.05 | 209.41 | 112.11 | -14.12 | 10.91 | |||||
Capital Expenditures, 2 Yr. CAGR % | -23.4 | -12.67 | 3.84 | 61.61 | 67.45 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | -39.87 | 1.6K | 184.27 | 44.64 | 69.28 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | -40.52 | 2.27K | 184.71 | 44.65 | 70.42 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 5.68 | -4.91 | 8.62 | 31.34 | 23.92 | |||||
Gross Profit, 3 Yr. CAGR % | 2.01 | -62.27 | 3.25 | 43.23 | 13.63 | |||||
EBITDA, 3 Yr. CAGR % | 83.33 | 15.5 | 132.09 | -66.9 | 104.57 | |||||
EBITA, 3 Yr. CAGR % | 52.1 | 22.38 | 98.14 | -50.8 | 4.28 | |||||
EBIT, 3 Yr. CAGR % | 54.13 | 23.18 | 98.3 | -50.03 | 18.79 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 55.32 | 23.82 | 150.37 | 124.16 | 111.46 | |||||
Net Income, 3 Yr. CAGR % | 55.32 | 23.82 | 150.37 | 124.16 | 111.46 | |||||
Normalized Net Income, 3 Yr. CAGR % | 54.51 | 23.9 | 151.48 | 38.23 | 36.44 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 47.1 | 17.37 | 124.36 | 92.64 | 81.41 | |||||
Accounts Receivable, 3 Yr. CAGR % | -13.14 | 14.45 | 46.52 | 54 | 37.02 | |||||
Inventory, 3 Yr. CAGR % | 28.82 | 15.13 | 11.98 | 73.12 | 7.82 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 2.45 | -1.86 | 45.99 | 10.05 | 20 | |||||
Total Assets, 3 Yr. CAGR % | 34.85 | 18.74 | 151.67 | 122.73 | 121.81 | |||||
Tangible Book Value, 3 Yr. CAGR % | 39.86 | 19.46 | 54.77 | -9.01 | -31.5 | |||||
Common Equity, 3 Yr. CAGR % | 38.62 | 19.04 | 94.84 | 95.88 | 102.17 | |||||
Cash From Operations, 3 Yr. CAGR % | 6.96 | 2.16 | 133.6 | 32.89 | 20.25 | |||||
Capital Expenditures, 3 Yr. CAGR % | 8.88 | -9.54 | -15.8 | 26.28 | 57.69 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | -7.96 | 3.52 | 772.27 | 85.93 | 94.83 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | -8.37 | 3.1 | 991.09 | 86.16 | 95.67 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 15.12 | 13.61 | 7.94 | 12.56 | 16.01 | |||||
Gross Profit, 5 Yr. CAGR % | 1.72 | -24.66 | 7.9 | 4.47 | 6.22 | |||||
EBITDA, 5 Yr. CAGR % | 24.71 | 29.88 | 85.11 | -51.56 | 142.48 | |||||
EBITA, 5 Yr. CAGR % | 52.68 | 26.4 | 62.35 | -35.77 | 47.46 | |||||
EBIT, 5 Yr. CAGR % | 53.9 | 26.9 | 62.43 | -35.16 | 59.5 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 59.31 | 27.08 | 86.82 | 60.58 | 122.72 | |||||
Net Income, 5 Yr. CAGR % | 59.31 | 27.08 | 86.82 | 60.58 | 122.72 | |||||
Normalized Net Income, 5 Yr. CAGR % | 58.53 | 27.13 | 87.45 | 19.84 | 73.42 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 53.31 | 22.21 | 72.57 | 44.34 | 99.15 | |||||
Accounts Receivable, 5 Yr. CAGR % | 20.12 | 8.26 | 8.03 | 40.38 | 44.23 | |||||
Inventory, 5 Yr. CAGR % | 39.7 | 24.03 | -0.24 | -17.41 | -8.42 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 6.52 | 1.49 | 28.75 | 28.83 | 31.53 | |||||
Total Assets, 5 Yr. CAGR % | 22.73 | 21.37 | 94.3 | 86.35 | 70.5 | |||||
Tangible Book Value, 5 Yr. CAGR % | 23.26 | 22.71 | 48.19 | 9.1 | -17.92 | |||||
Common Equity, 5 Yr. CAGR % | 22.29 | 21.83 | 69.42 | 72.16 | 57.13 | |||||
Cash From Operations, 5 Yr. CAGR % | 58.08 | 22.99 | 35.25 | -5.83 | 73.41 | |||||
Capital Expenditures, 5 Yr. CAGR % | -3.59 | -11.88 | 4.97 | 1.59 | 10.85 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 39.52 | 13 | 40.54 | 15.12 | 351.01 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 39.66 | 12.83 | 40.62 | 15.01 | 417.21 |
- Stock Market
- Equities
- FYB Stock
- Financials Formycon AG
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















